keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/27910097/chronic-migraine-an-update-on-physiology-imaging-and-the-mechanism-of-action-of-two-available-pharmacologic-therapies
#1
Sheena K Aurora, Mitchell F Brin
Several lines of research support the hypothesis that migraine is a spectrum of illness, with clinical symptoms that vary along a continuum from episodic migraine to chronic migraine. Physiologic changes may result in episodic migraine evolving into chronic migraine over months to years in susceptible individuals. With chronification, headache frequency increases, becoming more disabling and less responsive to therapy. Neurophysiologic and functional imaging research has reported that chronic migraine may be associated with severity-specific metabolic, functional, and structural abnormalities in the brainstem...
December 2, 2016: Headache
https://www.readbyqxmd.com/read/27908491/clinical-outcomes-of-botox-injections-for-chronic-temporomandibular-disorders-do-we-understand-how-botox-works-on-muscle-pain-and-the-brain
#2
S T Connelly, J Myung, R Gupta, G M Tartaglia, A Gizdulich, J Yang, R Silva
The main objective of this retrospective review was to analyze the clinical outcomes following the use of botulinum toxin (onabotulinumtoxinA, Botox) injections to relieve the symptoms of chronic temporomandibular disorders (TMD). Seventy-one patients with a diagnosis of TMD (according to the RDC/TMD international consortium) associated with or without bruxism and refractory to conventional treatment (e.g. oral appliances, physiotherapy, etc.) received Botox injections into the temporalis and masseter muscles...
November 28, 2016: International Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/27893541/treatment-of-palmar-hyperhidrosis-with-needle-injection-versus-low-pressure-needle-free-jet-injection-of-onabotulinumtoxina-an-open-label-prospective-study
#3
Sophie Vadeboncoeur, Vincent Richer, Mélissa Nantel-Battista, Antranik Benohanian
BACKGROUND: OnabotulinumtoxinA (OnabotA) injections are effective to treat palmar hyperhidrosis (HH) but are quite painful. OBJECTIVE: To evaluate efficacy and pain of OnabotA injection using a needle-free jet apparatus compared with the traditional needle injection to treat palmar HH. METHODS: Twenty patients were recruited for a prospective open-label study. Their right hand was injected with 1% lidocaine with a jet injector, after which OnabotA was injected with a needle...
November 23, 2016: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/27889830/urinary-retention-in-female-oab-after-intravesical-botox-injection-who-is-really-at-risk
#4
Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger
INTRODUCTION AND HYPOTHESIS: Intravesical onabotulinumtoxinA (Botox) injections are effective for the treatment of idiopathic overactive bladder (OAB) symptoms. The aim of our study was to assess the predisposing factors for urinary retention in women with OAB after intravesical Botox injection. METHODS: All participants were women of European descent with idiopathic OAB. OnabotulinumtoxinA (100 U) was administered in 20 intra-detrusor injections. Analysis was performed based on the results of safety assessments made during follow-up (FU) visits on weeks 2, 4 and 12, in 208 women who were treated with Botox injections for refractory OAB and who completed all FU visits...
November 26, 2016: International Urogynecology Journal
https://www.readbyqxmd.com/read/27884065/the-efficacy-of-2-formulations-of-botulinum-toxin-type-a-for-masseter-reduction-a-split-face-comparison-study
#5
Rungsima Wanitphakdeedecha, Chanida Ungaksornpairote, Arisa Kaewkes, Angkana Sathaworawong, Nittaya Lektrakul, Woraphong Manuskiatti
BACKGROUND: Botulinum toxin type A (BTA) is now extensively used to address cosmetic concerns. OnabotulinumtoxinA (ONA, Botox; Allergan Inc., Irvine, CA) received FDA approval for upper face rejuvenation, including glabella frown lines and crow's-feet lines. The other off-label uses for lower face conditions have been utilized for contouring purposes, especially masseter hypertrophy. Recently, a new Daewoong BTA, (Nabota, NBT, Daewoong Pharmaceutical, Seoul, Korea), was recently introduced...
November 25, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27814412/an-update-on-neurotoxin-products-and-administration-methods
#6
Julien Lanoue, Joanna Dong, Timothy Do, Gary Goldenberg
Since onabotulinumtoxinA for nonsurgical aesthetic enhancement of glabellar lines was initially reported, the popularity of botulinum neurotoxin (BoNT) products among both clinicians and consumers has rapidly grown, and we have seen several additional BoNT formulations enter the market. As the demand for minimally invasive cosmetic procedures continues to increase, we will see the introduction of additional formulations of BoNT products as well as new delivery devices and administration techniques. In this article, we provide a brief update on current and upcoming BoNT products and also review the literature on novel administration methods based on recently published studies...
September 2016: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/27790301/the-use-of-intra-detrusor-onabotulinumtoxina-in-patients-with-myasthenia-gravis
#7
Ian Wright, Andrea Civitarese, Richard Baverstock
The use of intra-detrusor onabotulinumtoxinA (Botox(®)) in patients with myasthenia gravis has not been reported, and little evidence exists to substantiate a complete contraindication of Botox use in this population. Here, we present two cases of comorbid overactive bladder (OAB) and myasthenia gravis successfully treated with intra-detrusor Botox.
May 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27789302/management-of-overactive-bladder-with-onabotulinumtoxina-systematic-review-and-meta-analysis
#8
Hugo E López Ramos, Lynda Torres Castellanos, Ingrid Ponce Esparza, Alejandro Jaramillo, Andrea Rodríguez, Camila Moreno Bencardino
OBJECTIVE: To evaluate the efficacy and safety of OnabotulinumtoxinA treatment in the management of overactive bladder syndrome. MATERIALS AND METHODS: A systematic review of the literature and meta-analysis was performed including randomized controlled clinical trials that compared the use of OnabotulinumtoxinA with placebo, antimuscarinic medication, or different doses of OnabotulinumtoxinA. Eleven studies met inclusion criteria and did not have any exclusion criteria...
October 24, 2016: Urology
https://www.readbyqxmd.com/read/27782297/botulinum-toxin-type-a-versus-botulinum-toxin-type-b-for-cervical-dystonia
#9
REVIEW
Gonçalo S Duarte, Mafalda Castelão, Filipe B Rodrigues, Raquel E Marques, Joaquim Ferreira, Cristina Sampaio, Austen P Moore, João Costa
BACKGROUND: This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this condition. Botulinum toxin type B (BtB) is an alternative option, with no compelling theoretical reason why it might not be as- or even more effective - than BtA...
October 26, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27776965/experience-with-botulinum-toxin-in-chronic-migraine
#10
A Castrillo Sanz, N Morollón Sánchez-Mateos, C Simonet Hernández, B Fernández Rodríguez, D Cerdán Santacruz, A Mendoza Rodríguez, M F Rodríguez Sanz, C Tabernero García, P Guerrero Becerra, M Ferrero Ros, J Duate García-Luis
OBJECTIVE: The purposes of this study were to describe our 16-month experience with onabotulinumtoxinA (OnabotA) for the treatment of chronic migraine (CM) in the Spanish province of Segovia, evaluate its benefits, and determine clinical markers of good response to treatment. PATIENTS AND METHODS: Prospective study of patients with CM who received OnabotA for 16 months. The effectiveness of OnabotA was evaluated based on the reduction in the number of headache days, pain intensity, and side effects...
October 21, 2016: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/27774495/impact-of-cervical-dystonia-on-work-productivity-an-analysis-from-a-patient-registry
#11
Eric S Molho, Mark Stacy, Patrick Gillard, David Charles, Charles H Adler, Joseph Jankovic, Marc Schwartz, Mitchell F Brin
BACKGROUND: Cervical dystonia is thought to result in high disease burden, but limited information exists on its impact on employment and work productivity. We utilized data from the Cervical Dystonia Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (ClinicalTrials.gov identifier: NCT00836017) to assess the impact of cervical dystonia on employment and work productivity and examine the effect of onabotulinumtoxinA treatments on work productivity. METHODS: Subjects completed a questionnaire on employment status and work productivity at baseline and final visit...
March 2016: Movement Disorders Clinical Practice
https://www.readbyqxmd.com/read/27766076/brain-changes-in-responders-vs-non-responders-in-chronic-migraine-markers-of-disease-reversal
#12
Catherine S Hubbard, Lino Becerra, Jonathan H Smith, Justin M DeLange, Ryan M Smith, David F Black, Kirk M Welker, Rami Burstein, Fred M Cutrer, David Borsook
The aim of this study was to identify structural and functional brain changes that accompanied the transition from chronic (CM; ≥15 headache days/month) to episodic (EM; <15 headache days/month) migraine following prophylactic treatment with onabotulinumtoxinA (BoNT-A). Specifically, we examined whether CM patients responsive to prophylaxis (responders; n = 11), as evidenced by a reversal in disease status (defined by at least a 50% reduction in migraine frequency and <15 headache days/month), compared to CM patients whose migraine frequency remained unchanged (non-responders; n = 12), showed differences in cortical thickness using surface-based morphometry...
2016: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/27742453/onabotulinumtoxina-is-preferred-over-sacral-neuromodulation-for-refractory-overactive-bladder
#13
David A Ginsberg
No abstract text is available yet for this article.
October 11, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27742452/onabotulinumtoxina-is-preferred-over-sacral-neuromodulation-for-refractory-overactive-bladder
#14
Steven Siegel
No abstract text is available yet for this article.
October 11, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27733091/intra-articular-onabotulinumtoxina-in-osteoarthritis-knee-pain-effect-on-human-mechanistic-pain-biomarkers-and-clinical-pain
#15
L Arendt-Nielsen, G-L Jiang, R DeGryse, C C Turkel
OBJECTIVES: OnabotulinumtoxinA (onabotA) attenuates peripheral nociceptive transduction and consequently neuronal firing. The aim of this mechanistic study was to evaluate the effect of intra-articular (IA) onabotA in patients with painful knee osteoarthritis (OA). METHOD: We conducted a double-blind, randomized, placebo-controlled, 12-week trial using a single ultrasound-guided IA injection of onabotA (200 U). Patients (N = 121) were randomized to receive onabotA (n = 61) or placebo (n = 60)...
October 13, 2016: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/27701762/impact-of-intravesical-onabotulinumtoxina-on-sexual-function-in-women-with-oab
#16
Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger
AIMS: Urgency urinary incontinence (UUI), and the symptoms of overactive bladder (OAB) have a negative impact on female sexual function. The aim of this study was to investigate the effect of intravesical onabotulinumtoxinA (Botox) injection on sexual function in women with OAB, using the multi domain Female Sexual Function Index (FSFI) questionnaire. METHODS: Sixty-eight sexually active women with idiopathic OAB with at least one episode of UUI and ≥8 micturitions per 24 h were recruited...
October 4, 2016: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/27701661/onabotulinumtoxina-vs-sacral-neuromodulation-on-refractory-urgency-urinary-incontinence-in-women-a-randomized-clinical-trial
#17
Cindy L Amundsen, Holly E Richter, Shawn A Menefee, Yuko M Komesu, Lily A Arya, W Thomas Gregory, Deborah L Myers, Halina M Zyczynski, Sandip Vasavada, Tracy L Nolen, Dennis Wallace, Susan F Meikle
Importance: Women with refractory urgency urinary incontinence are treated with sacral neuromodulation and onabotulinumtoxinA with limited comparative information. Objective: To assess whether onabotulinumtoxinA is superior to sacral neuromodulation in controlling refractory episodes of urgency urinary incontinence. Design, Setting, and Participants: Multicenter open-label randomized trial (February 2012-January 2015) at 9 US medical centers involving 381 women with refractory urgency urinary incontinence...
October 4, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27673163/poster-411-the-impact-of-onabotulinumtoxina-on-severe-headache-days-preempt-24-week-pooled-analysis
#18
Sheena Aurora, Rashmi Halker, Patricia Pozo-Rosich, Ronald DeGryse, Aubrey Manack Adams, Manjit Matharu
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/27673114/poster-361-impact-of-early-intervention-with-onabotulinumtoxina-treatment-in-adult-patients-with-post-stroke-lower-limb-spasticity
#19
Atul T Patel, Anthony B Ward, Carolyn Geis, Chengcheng Liu, Wolfgang H Jost, Rozalina Dimitrova
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/27673106/poster-354-onabotulinumtoxina-to-treat-common-postures-in-post-stroke-lower-limb-spasticity-identification-of-a-treatment-paradigm
#20
Alberto Esquenazi, Khashayar Dashtipour, Abraham Alfaro, Ziyad Ayyoub, David Charles, Glenn D Graham, John R McGuire, Ib R Odderson, Atul T Patel, David M Simpson
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"